TY - JOUR
T1 - Antihypertensive utility of perindopril in a large, general practice-based clinical trial.
AU - Julius, Stevo
AU - Cohn, Jay N.
AU - Neutel, Joel
AU - Weber, Michael
AU - Turlapaty, Prasad
AU - Shen, Yannan
AU - Dong, Victor
AU - Batchelor, Alicia
AU - Lagast, Hjalmar
PY - 2004/1
Y1 - 2004/1
N2 - The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.
AB - The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.
UR - http://www.scopus.com/inward/record.url?scp=1642428445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642428445&partnerID=8YFLogxK
U2 - 10.1111/j.1524-6175.2004.02440.x
DO - 10.1111/j.1524-6175.2004.02440.x
M3 - Article
C2 - 14724419
AN - SCOPUS:1642428445
SN - 1524-6175
VL - 6
SP - 10
EP - 17
JO - Journal of clinical hypertension (Greenwich, Conn.)
JF - Journal of clinical hypertension (Greenwich, Conn.)
IS - 1
ER -